Antibody induced neutrophil and macrophage tissue pathology in renal allografts

同种异体肾移植物中抗体诱导的中性粒细胞和巨噬细胞组织病理学

基本信息

  • 批准号:
    9086202
  • 负责人:
  • 金额:
    $ 38.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-01 至 2020-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary / Abstract Antibody-mediated mechanisms leading to acute and chronic renal allograft injury and loss remain poorly understood. Investigation into these mechanisms is hampered by the lack of appropriate animal models to study the development of allograft injury as the donor-specific antibody (DSA) response is initiated and increases. We have developed a novel model of antibody-mediated rejection (AMR) of renal allografts in CCR5-/- recipients where the titers of DSA elicited in response to complete MHC-mismatched renal allografts are >50-fold higher than those elicited in wild-type recipients. The renal allografts are acutely rejected by this antibody response in CCR5-/- recipients between days 17 and 22 with heavy deposition of C3d, peritubular edema, and neutrophil and macrophage infiltration and activation including production of myeloperoxidase (MPO), histopathologic features of rejection that are characteristic of those observed during AMR in clinical transplants. These and our preliminary results have led us to propose the hypothesis that a key mechanism underlying acute and chronic AMR of renal allografts is the induced infiltration and activation of neutrophils and macrophages in the graft, which directly cause the acute and chronic graft tissue injury and increase the target antigens of the recipient antibody response. This hypothesis will be tested in three specific aims. In Specific Aim 1 we will identify and test the role of MPO-producing cells during antibody-mediated acute rejection of renal allografts in CCR5-/- recipients. In Specific Aim 2 we will test the role of neutrophil and macrophage mediated allograft tissue damage in the generation of donor MHC- and autoantigen-specific antibodies in response to renal allografts. In Specific Aim 3 we will use a B cell depletion strategy to test the molecular mechanisms leading to the development of antibody-mediated interstitital fibrosis and tubular atrophy in the renal allografts. These studies will utilize novel models of antibody-mediated acute and chronic renal allograft injury to provide new insights into mechanisms underlying these pathologies that remain a major problem undermining the success of renal transplantation. We anticipate the results of these studies will indicate new therapeutic targets to inhibit or attenuate antibody-mediated graft injury.
项目总结/摘要 抗体介导的机制导致急性和慢性肾移植损伤和损失仍然很差 明白对这些机制的研究由于缺乏适当的动物模型而受到阻碍, 研究供体特异性抗体(DSA)反应启动时同种异体移植损伤的发展, 增大我们建立了一种新的同种异体肾移植抗体介导的排斥反应(AMR)模型, CCR 5-/-受体,其中DSA滴度响应于完全MHC不匹配的肾移植物而引起 比在野生型受体中引发的高>50倍。同种异体肾移植会被这种 CCR 5-/-受体在第17天至第22天之间的抗体应答,C3 d、肾小管周围 水肿、中性粒细胞和巨噬细胞浸润和活化,包括髓过氧化物酶的产生 (MPO)排斥反应的组织病理学特征是临床AMR期间观察到的特征。 移植这些和我们的初步结果使我们提出了一个假设,即一个关键机制 肾移植物的潜在急性和慢性AMR是诱导的中性粒细胞的浸润和活化, 移植物中的巨噬细胞,其直接引起急性和慢性移植组织损伤,并增加靶向 受体抗体反应的抗原。这一假设将在三个具体目标中得到检验。在特定 目的1:我们将鉴定和检测MPO产生细胞在抗体介导的急性排斥反应中的作用。 CCR 5-/-受体的肾移植。在具体目标2中,我们将测试中性粒细胞和巨噬细胞的作用 介导的同种异体移植组织损伤在供体MHC和自身抗原特异性抗体的产生中的作用 对肾移植的反应在特定目标3中,我们将使用B细胞耗竭策略来检测分子水平。 导致抗体介导的胰腺纤维化和肾小管萎缩的机制 肾移植这些研究将利用抗体介导的急性和慢性肾移植的新模型 损伤提供了新的见解,这些病理机制仍然是一个主要问题, 破坏了肾移植的成功我们预计这些研究的结果将表明新的 治疗靶点以抑制或减弱抗体介导的移植物损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert L Fairchild其他文献

MACROPHAGE RECRUITMENT AND IL-10 INDUCTION CORRELATE WITH PROTECTION PROVIDED BY RENAL ISCHEMIC PRECONDITIONING ATTENUATES RENAL ISCHEMIA/REPERFUSION INJURY
  • DOI:
    10.1016/s0022-5347(08)62029-7
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Nobuyuki Fukuzawa;Austin D Schenk;Katsuya Nonomura;Robert L Fairchild
  • 通讯作者:
    Robert L Fairchild

Robert L Fairchild的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert L Fairchild', 18)}}的其他基金

Targeting the transcriptional co-activators YAP and TAZ with statins to prevent solid organ transplant rejection by HLA donor specific antibodies
用他汀类药物靶向转录共激活剂 YAP 和 TAZ,以防止 HLA 供体特异性抗体导致实体器官移植排斥
  • 批准号:
    10734277
  • 财政年份:
    2023
  • 资助金额:
    $ 38.23万
  • 项目类别:
Post-transcriptional regulation of gene expression by microRNAs in antibody-mediated rejection
抗体介导的排斥反应中 microRNA 对基因表达的转录后调控
  • 批准号:
    10522285
  • 财政年份:
    2022
  • 资助金额:
    $ 38.23万
  • 项目类别:
Chronic Antibody-Mediated Rejection of Kidney Allografts
慢性抗体介导的同种异体肾移植排斥
  • 批准号:
    10416460
  • 财政年份:
    2022
  • 资助金额:
    $ 38.23万
  • 项目类别:
Post-transcriptional regulation of gene expression by microRNAs in antibody-mediated rejection
抗体介导的排斥反应中 microRNA 对基因表达的转录后调控
  • 批准号:
    10693399
  • 财政年份:
    2022
  • 资助金额:
    $ 38.23万
  • 项目类别:
Chronic Antibody-Mediated Rejection of Kidney Allografts
慢性抗体介导的同种异体肾移植排斥
  • 批准号:
    10557880
  • 财政年份:
    2022
  • 资助金额:
    $ 38.23万
  • 项目类别:
Post-transcriptional regulation of gene expression by microRNAs in antibody-mediated rejection.
抗体介导的排斥反应中 microRNA 对基因表达的转录后调控。
  • 批准号:
    10475333
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
Acute Antibody Mediated Kidney Allograft Rejection
急性抗体介导的同种异体移植肾排斥反应
  • 批准号:
    10490876
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
Acute Antibody Mediated Kidney Allograft Rejection
急性抗体介导的同种异体移植肾排斥反应
  • 批准号:
    10362234
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
Acute Antibody Mediated Kidney Allograft Rejection
急性抗体介导的同种异体移植肾排斥反应
  • 批准号:
    10683315
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
Antibody-Mediated Rejection of Renal Allografts
抗体介导的同种异体肾移植排斥
  • 批准号:
    8932396
  • 财政年份:
    2010
  • 资助金额:
    $ 38.23万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 38.23万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 38.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了